These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S, Yeap B, Vogl S, Carbone P. Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766 [Abstract] [Full Text] [Related]
3. Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy. Hainsworth JD, Malcolm A, Johnson DH, Burnett LS, Jones HW, Greco FA. Obstet Gynecol; 1983 May 15; 61(5):619-23. PubMed ID: 6403897 [Abstract] [Full Text] [Related]
4. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II). Vogl SE, Berenzweig M, Kaplan BH, Moukhtar M, Bulkin W. Cancer Treat Rep; 1979 Feb 15; 63(2):311-7. PubMed ID: 109202 [Abstract] [Full Text] [Related]
17. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Berek JS, Markman M, Blessing JA, Kucera PR, Nelson BE, Anderson B, Hanjani P. Gynecol Oncol; 1999 Jul 15; 74(1):48-52. PubMed ID: 10385550 [Abstract] [Full Text] [Related]